18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value
Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tessonnier, L. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2012 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Société Internationale de Chirurgie 2012 |
|---|
| Übergeordnetes Werk: |
Enthalten in: World Journal of Surgery - Springer-Verlag, 1996, 37(2012), 1 vom: 22. Sept., Seite 107-112 |
|---|---|
| Übergeordnetes Werk: |
volume:37 ; year:2012 ; number:1 ; day:22 ; month:09 ; pages:107-112 |
| Links: |
|---|
| DOI / URN: |
10.1007/s00268-012-1802-y |
|---|
| Katalog-ID: |
SPR003439925 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR003439925 | ||
| 003 | DE-627 | ||
| 005 | 20230519101546.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201001s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00268-012-1802-y |2 doi | |
| 035 | |a (DE-627)SPR003439925 | ||
| 035 | |a (SPR)s00268-012-1802-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tessonnier, L. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value |
| 264 | 1 | |c 2012 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Société Internationale de Chirurgie 2012 | ||
| 520 | |a Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. | ||
| 650 | 4 | |a Overall Survival |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Standardize Uptake Value |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Adrenocortical Carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mitotane |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Standardize Uptake Value Ratio |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Ansquer, C. |4 aut | |
| 700 | 1 | |a Bournaud, C. |4 aut | |
| 700 | 1 | |a Sebag, F. |4 aut | |
| 700 | 1 | |a Mirallié, E. |4 aut | |
| 700 | 1 | |a Lifante, J. C. |4 aut | |
| 700 | 1 | |a Palazzo, F. F. |4 aut | |
| 700 | 1 | |a Morange, I. |4 aut | |
| 700 | 1 | |a Drui, D. |4 aut | |
| 700 | 1 | |a de la Foucardère, C. |4 aut | |
| 700 | 1 | |a Mancini, J. |4 aut | |
| 700 | 1 | |a Taïeb, D. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t World Journal of Surgery |d Springer-Verlag, 1996 |g 37(2012), 1 vom: 22. Sept., Seite 107-112 |w (DE-627)SPR003391159 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2012 |g number:1 |g day:22 |g month:09 |g pages:107-112 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00268-012-1802-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2012 |e 1 |b 22 |c 09 |h 107-112 | ||
| author_variant |
l t lt c a ca c b cb f s fs e m em j c l jc jcl f f p ff ffp i m im d d dd l f c d lfc lfcd j m jm d t dt |
|---|---|
| matchkey_str |
tessonnierlansquercbournaudcsebagfmirall:2012----:8fgpaetntasaigfharncriacnesdansito |
| hierarchy_sort_str |
2012 |
| publishDate |
2012 |
| allfields |
10.1007/s00268-012-1802-y doi (DE-627)SPR003439925 (SPR)s00268-012-1802-y-e DE-627 ger DE-627 rakwb eng Tessonnier, L. verfasserin aut 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2012 Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. Overall Survival (dpeaa)DE-He213 Standardize Uptake Value (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Standardize Uptake Value Ratio (dpeaa)DE-He213 Ansquer, C. aut Bournaud, C. aut Sebag, F. aut Mirallié, E. aut Lifante, J. C. aut Palazzo, F. F. aut Morange, I. aut Drui, D. aut de la Foucardère, C. aut Mancini, J. aut Taïeb, D. aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 37(2012), 1 vom: 22. Sept., Seite 107-112 (DE-627)SPR003391159 nnns volume:37 year:2012 number:1 day:22 month:09 pages:107-112 https://dx.doi.org/10.1007/s00268-012-1802-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 37 2012 1 22 09 107-112 |
| spelling |
10.1007/s00268-012-1802-y doi (DE-627)SPR003439925 (SPR)s00268-012-1802-y-e DE-627 ger DE-627 rakwb eng Tessonnier, L. verfasserin aut 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2012 Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. Overall Survival (dpeaa)DE-He213 Standardize Uptake Value (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Standardize Uptake Value Ratio (dpeaa)DE-He213 Ansquer, C. aut Bournaud, C. aut Sebag, F. aut Mirallié, E. aut Lifante, J. C. aut Palazzo, F. F. aut Morange, I. aut Drui, D. aut de la Foucardère, C. aut Mancini, J. aut Taïeb, D. aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 37(2012), 1 vom: 22. Sept., Seite 107-112 (DE-627)SPR003391159 nnns volume:37 year:2012 number:1 day:22 month:09 pages:107-112 https://dx.doi.org/10.1007/s00268-012-1802-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 37 2012 1 22 09 107-112 |
| allfields_unstemmed |
10.1007/s00268-012-1802-y doi (DE-627)SPR003439925 (SPR)s00268-012-1802-y-e DE-627 ger DE-627 rakwb eng Tessonnier, L. verfasserin aut 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2012 Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. Overall Survival (dpeaa)DE-He213 Standardize Uptake Value (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Standardize Uptake Value Ratio (dpeaa)DE-He213 Ansquer, C. aut Bournaud, C. aut Sebag, F. aut Mirallié, E. aut Lifante, J. C. aut Palazzo, F. F. aut Morange, I. aut Drui, D. aut de la Foucardère, C. aut Mancini, J. aut Taïeb, D. aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 37(2012), 1 vom: 22. Sept., Seite 107-112 (DE-627)SPR003391159 nnns volume:37 year:2012 number:1 day:22 month:09 pages:107-112 https://dx.doi.org/10.1007/s00268-012-1802-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 37 2012 1 22 09 107-112 |
| allfieldsGer |
10.1007/s00268-012-1802-y doi (DE-627)SPR003439925 (SPR)s00268-012-1802-y-e DE-627 ger DE-627 rakwb eng Tessonnier, L. verfasserin aut 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2012 Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. Overall Survival (dpeaa)DE-He213 Standardize Uptake Value (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Standardize Uptake Value Ratio (dpeaa)DE-He213 Ansquer, C. aut Bournaud, C. aut Sebag, F. aut Mirallié, E. aut Lifante, J. C. aut Palazzo, F. F. aut Morange, I. aut Drui, D. aut de la Foucardère, C. aut Mancini, J. aut Taïeb, D. aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 37(2012), 1 vom: 22. Sept., Seite 107-112 (DE-627)SPR003391159 nnns volume:37 year:2012 number:1 day:22 month:09 pages:107-112 https://dx.doi.org/10.1007/s00268-012-1802-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 37 2012 1 22 09 107-112 |
| allfieldsSound |
10.1007/s00268-012-1802-y doi (DE-627)SPR003439925 (SPR)s00268-012-1802-y-e DE-627 ger DE-627 rakwb eng Tessonnier, L. verfasserin aut 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value 2012 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Société Internationale de Chirurgie 2012 Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. Overall Survival (dpeaa)DE-He213 Standardize Uptake Value (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Standardize Uptake Value Ratio (dpeaa)DE-He213 Ansquer, C. aut Bournaud, C. aut Sebag, F. aut Mirallié, E. aut Lifante, J. C. aut Palazzo, F. F. aut Morange, I. aut Drui, D. aut de la Foucardère, C. aut Mancini, J. aut Taïeb, D. aut Enthalten in World Journal of Surgery Springer-Verlag, 1996 37(2012), 1 vom: 22. Sept., Seite 107-112 (DE-627)SPR003391159 nnns volume:37 year:2012 number:1 day:22 month:09 pages:107-112 https://dx.doi.org/10.1007/s00268-012-1802-y lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 37 2012 1 22 09 107-112 |
| language |
English |
| source |
Enthalten in World Journal of Surgery 37(2012), 1 vom: 22. Sept., Seite 107-112 volume:37 year:2012 number:1 day:22 month:09 pages:107-112 |
| sourceStr |
Enthalten in World Journal of Surgery 37(2012), 1 vom: 22. Sept., Seite 107-112 volume:37 year:2012 number:1 day:22 month:09 pages:107-112 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Overall Survival Standardize Uptake Value Adrenocortical Carcinoma Mitotane Standardize Uptake Value Ratio |
| isfreeaccess_bool |
false |
| container_title |
World Journal of Surgery |
| authorswithroles_txt_mv |
Tessonnier, L. @@aut@@ Ansquer, C. @@aut@@ Bournaud, C. @@aut@@ Sebag, F. @@aut@@ Mirallié, E. @@aut@@ Lifante, J. C. @@aut@@ Palazzo, F. F. @@aut@@ Morange, I. @@aut@@ Drui, D. @@aut@@ de la Foucardère, C. @@aut@@ Mancini, J. @@aut@@ Taïeb, D. @@aut@@ |
| publishDateDaySort_date |
2012-09-22T00:00:00Z |
| hierarchy_top_id |
SPR003391159 |
| id |
SPR003439925 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003439925</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519101546.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00268-012-1802-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003439925</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00268-012-1802-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tessonnier, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Société Internationale de Chirurgie 2012</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Overall Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Standardize Uptake Value</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adrenocortical Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mitotane</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Standardize Uptake Value Ratio</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ansquer, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bournaud, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebag, F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mirallié, E.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lifante, J. C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palazzo, F. F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morange, I.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drui, D.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de la Foucardère, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mancini, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taïeb, D.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">World Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 1996</subfield><subfield code="g">37(2012), 1 vom: 22. Sept., Seite 107-112</subfield><subfield code="w">(DE-627)SPR003391159</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1</subfield><subfield code="g">day:22</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:107-112</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00268-012-1802-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2012</subfield><subfield code="e">1</subfield><subfield code="b">22</subfield><subfield code="c">09</subfield><subfield code="h">107-112</subfield></datafield></record></collection>
|
| author |
Tessonnier, L. |
| spellingShingle |
Tessonnier, L. misc Overall Survival misc Standardize Uptake Value misc Adrenocortical Carcinoma misc Mitotane misc Standardize Uptake Value Ratio 18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value |
| authorStr |
Tessonnier, L. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR003391159 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value Overall Survival (dpeaa)DE-He213 Standardize Uptake Value (dpeaa)DE-He213 Adrenocortical Carcinoma (dpeaa)DE-He213 Mitotane (dpeaa)DE-He213 Standardize Uptake Value Ratio (dpeaa)DE-He213 |
| topic |
misc Overall Survival misc Standardize Uptake Value misc Adrenocortical Carcinoma misc Mitotane misc Standardize Uptake Value Ratio |
| topic_unstemmed |
misc Overall Survival misc Standardize Uptake Value misc Adrenocortical Carcinoma misc Mitotane misc Standardize Uptake Value Ratio |
| topic_browse |
misc Overall Survival misc Standardize Uptake Value misc Adrenocortical Carcinoma misc Mitotane misc Standardize Uptake Value Ratio |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
World Journal of Surgery |
| hierarchy_parent_id |
SPR003391159 |
| hierarchy_top_title |
World Journal of Surgery |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR003391159 |
| title |
18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value |
| ctrlnum |
(DE-627)SPR003439925 (SPR)s00268-012-1802-y-e |
| title_full |
18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value |
| author_sort |
Tessonnier, L. |
| journal |
World Journal of Surgery |
| journalStr |
World Journal of Surgery |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2012 |
| contenttype_str_mv |
txt |
| container_start_page |
107 |
| author_browse |
Tessonnier, L. Ansquer, C. Bournaud, C. Sebag, F. Mirallié, E. Lifante, J. C. Palazzo, F. F. Morange, I. Drui, D. de la Foucardère, C. Mancini, J. Taïeb, D. |
| container_volume |
37 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tessonnier, L. |
| doi_str_mv |
10.1007/s00268-012-1802-y |
| title_sort |
18f-fdg uptake at initial staging of the adrenocortical cancers: a diagnostic tool but not of prognostic value |
| title_auth |
18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value |
| abstract |
Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. © Société Internationale de Chirurgie 2012 |
| abstractGer |
Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. © Société Internationale de Chirurgie 2012 |
| abstract_unstemmed |
Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values. © Société Internationale de Chirurgie 2012 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value |
| url |
https://dx.doi.org/10.1007/s00268-012-1802-y |
| remote_bool |
true |
| author2 |
Ansquer, C. Bournaud, C. Sebag, F. Mirallié, E. Lifante, J. C. Palazzo, F. F. Morange, I. Drui, D. de la Foucardère, C. Mancini, J. Taïeb, D. |
| author2Str |
Ansquer, C. Bournaud, C. Sebag, F. Mirallié, E. Lifante, J. C. Palazzo, F. F. Morange, I. Drui, D. de la Foucardère, C. Mancini, J. Taïeb, D. |
| ppnlink |
SPR003391159 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s00268-012-1802-y |
| up_date |
2024-07-03T19:30:01.626Z |
| _version_ |
1803587421866033152 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR003439925</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519101546.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201001s2012 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s00268-012-1802-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR003439925</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s00268-012-1802-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tessonnier, L.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">18F-FDG Uptake at Initial Staging of the Adrenocortical Cancers: A Diagnostic Tool but Not of Prognostic Value</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2012</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Société Internationale de Chirurgie 2012</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. 18F-FDG PET (18F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, 18F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative 18F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. Methods A retrospective analysis was performed in patients who underwent 18F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; 18F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All 18F-FDG PET/CT procedures were reinterpreted in a blind fashion. Results Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)max = 11 (range: 3–56) and a tumor/liver $ SUV_{max} $ ratio = 4.2 (range: 1.3–15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. 18F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. Conclusions At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Overall Survival</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Standardize Uptake Value</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adrenocortical Carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mitotane</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Standardize Uptake Value Ratio</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ansquer, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bournaud, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sebag, F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mirallié, E.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lifante, J. C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Palazzo, F. F.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morange, I.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drui, D.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de la Foucardère, C.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mancini, J.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taïeb, D.</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">World Journal of Surgery</subfield><subfield code="d">Springer-Verlag, 1996</subfield><subfield code="g">37(2012), 1 vom: 22. Sept., Seite 107-112</subfield><subfield code="w">(DE-627)SPR003391159</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:37</subfield><subfield code="g">year:2012</subfield><subfield code="g">number:1</subfield><subfield code="g">day:22</subfield><subfield code="g">month:09</subfield><subfield code="g">pages:107-112</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s00268-012-1802-y</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">37</subfield><subfield code="j">2012</subfield><subfield code="e">1</subfield><subfield code="b">22</subfield><subfield code="c">09</subfield><subfield code="h">107-112</subfield></datafield></record></collection>
|
| score |
7.3995275 |